Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance - PubMed (original) (raw)
. 2007 Nov 1;67(21):10546-55.
doi: 10.1158/0008-5472.CAN-07-2765.
Adri Recio, Rosemarie Mick, Carolyn E Clark, Erica L Carpenter, Kevin R Fox, Angela DeMichele, Lynn M Schuchter, Michael S Leibowitz, Michael H Wexler, Barbara A Vance, Gregory L Beatty, Elizabeth Veloso, Michael D Feldman, Robert H Vonderheide
Affiliations
- PMID: 17974999
- DOI: 10.1158/0008-5472.CAN-07-2765
Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance
Susan M Domchek et al. Cancer Res. 2007.
Abstract
The human telomerase reverse transcriptase (hTERT) is nearly universally overexpressed in human cancer, contributes critically to oncogenesis, and is recognized by cytotoxic T cells that lyse tumors. CD8+ T cells specific for hTERT naturally occur in certain populations of cancer patients in remission, but it remains poorly understood whether such T cells could contribute to tumor immunosurveillance. To address this issue, we induced hTERT-specific T cells in vivo via peptide vaccination in 19 patients with metastatic breast cancer who otherwise had no measurable T-cell responses to hTERT at baseline. Tumor-infiltrating lymphocytes (TIL) were evident after, but not before vaccination, with 4% to 13% of postvaccine CD8+ TIL specific for the immunizing hTERT peptide. Induction of TIL manifested clinically with tumor site pain and pruritus and pathologically with alterations in the tumor microenvironment, featuring histiocytic accumulation and widespread tumor necrosis. hTERT-specific CD8+ T cells were also evident after vaccination in the peripheral blood of patients and exhibited effector functions in vitro including proliferation, IFN-gamma production, and tumor lysis. An exploratory landmark analysis revealed that median overall survival was significantly longer in those patients who achieved an immune response to hTERT peptide compared with patients who did not. Immune response to a control cytomegalovirus peptide in the vaccine did not correlate with survival. These results suggest that hTERT-specific T cells could contribute to the immunosurveillance of breast cancer and suggest novel opportunities for both therapeutic and prophylactic vaccine strategies for cancer.
Similar articles
- In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer.
Amarnath SM, Dyer CE, Ramesh A, Iwuagwu O, Drew PJ, Greenman J. Amarnath SM, et al. Int J Oncol. 2004 Jul;25(1):211-7. Int J Oncol. 2004. PMID: 15202008 - Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma.
Mizukoshi E, Nakagawa H, Kitahara M, Yamashita T, Arai K, Sunagozaka H, Fushimi K, Kobayashi E, Kishi H, Muraguchi A, Kaneko S. Mizukoshi E, et al. Cancer Lett. 2015 Aug 10;364(2):98-105. doi: 10.1016/j.canlet.2015.04.031. Epub 2015 May 14. Cancer Lett. 2015. PMID: 25982205 - Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.
Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM. Vonderheide RH, et al. Clin Cancer Res. 2004 Feb 1;10(3):828-39. doi: 10.1158/1078-0432.ccr-0620-3. Clin Cancer Res. 2004. PMID: 14871958 Clinical Trial. - Telomerase in cancer immunotherapy.
Liu JP, Chen W, Schwarer AP, Li H. Liu JP, et al. Biochim Biophys Acta. 2010 Jan;1805(1):35-42. doi: 10.1016/j.bbcan.2009.09.001. Epub 2009 Sep 12. Biochim Biophys Acta. 2010. PMID: 19751801 Review. - Prospects and challenges of building a cancer vaccine targeting telomerase.
Vonderheide RH. Vonderheide RH. Biochimie. 2008 Jan;90(1):173-80. doi: 10.1016/j.biochi.2007.07.005. Epub 2007 Jul 17. Biochimie. 2008. PMID: 17716803 Free PMC article. Review.
Cited by
- Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.
Yan J, Pankhong P, Shin TH, Obeng-Adjei N, Morrow MP, Walters JN, Khan AS, Sardesai NY, Weiner DB. Yan J, et al. Cancer Immunol Res. 2013 Sep;1(3):179-189. doi: 10.1158/2326-6066.CIR-13-0001. Epub 2013 Jul 17. Cancer Immunol Res. 2013. PMID: 24777680 Free PMC article. - Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001.
Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G. Inderberg-Suso EM, et al. Oncoimmunology. 2012 Aug 1;1(5):670-686. doi: 10.4161/onci.20426. Oncoimmunology. 2012. PMID: 22934259 Free PMC article. - Progress in the development of a therapeutic vaccine for breast cancer.
Coveler AL, Bates NE, Disis ML. Coveler AL, et al. Breast Cancer (Dove Med Press). 2010 Jun 4;2:25-36. doi: 10.2147/bctt.s6956. Breast Cancer (Dove Med Press). 2010. PMID: 24367164 Free PMC article. Review. - Vaccination of patients with cutaneous melanoma with telomerase-specific peptides.
Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, Møller M, Eriksen JA, Rasmussen AM, Braathen LR, Gaudernack G. Hunger RE, et al. Cancer Immunol Immunother. 2011 Nov;60(11):1553-64. doi: 10.1007/s00262-011-1061-z. Epub 2011 Jun 17. Cancer Immunol Immunother. 2011. PMID: 21681371 Free PMC article. Clinical Trial. - Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates.
Dharmapuri S, Peruzzi D, Mennuni C, Calvaruso F, Giampaoli S, Barbato G, Kandimalla ER, Agrawal S, Scarselli E, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L. Dharmapuri S, et al. Mol Ther. 2009 Oct;17(10):1804-13. doi: 10.1038/mt.2009.165. Epub 2009 Jul 21. Mol Ther. 2009. PMID: 19623161 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials